OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - SANOFI Share Price

Certificat

DE000CL7PR29

Real-time Boerse Frankfurt Warrants 20:47:59 24/05/2024 BST
1.54 EUR -3.75% Intraday chart for OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - SANOFI
1 month+37.50%
3 months+6.94%
Date Price Change
24/05/24 1.54 -3.75%
23/05/24 1.6 -13.51%
22/05/24 1.85 +16.35%
21/05/24 1.59 +4.61%
20/05/24 1.52 -1.30%

Real-time Boerse Frankfurt Warrants

Last update May 24, 2024 at 08:47 pm

More quotes

Static data

Product typeKnock-Out with Stop Loss
Buy / SellCALL
Underlying SANOFI
IssuerLogo Issuer Société Générale Société Générale
WKN CL7PR2
ISINDE000CL7PR29
Date issued 08/04/2020
Strike 74.19
Maturity Unlimited
Parity 10 : 1
Emission price 1.03
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.45
Lowest since issue 0.25
Spread 0.11
Spread %6.92%

Company Profile

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Sector
-
More about the company

Ratings for Sanofi

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Sanofi

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
89.52 EUR
Average target price
108.2 EUR
Spread / Average Target
+20.86%
Consensus